Drugs / TAK-733
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01613261 | Aug 2013 → Sep 2015 | neoplasm | Millennium Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT00948467 | Dec 2009 → Apr 2013 | melanoma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05552755 | Jul 2023 → Jun 2027 expected | classic familial adenomatous polyposis | Recursion Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06005974 | Jan 2024 → Feb 2025 | neoplasm | Recursion Pharmaceuticals Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-733 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01613261 ↗ |
| Known as | Mek inhibitor tak-733 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1615025 ↗ |
| Known as | REC-4881 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05552755 ↗ |
| Action | Inhibit | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1615025 ↗2“Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL1615025 ↗ “an Oral MEK Inhibitor” NCT00948467 ↗ |
| Modality | Small molecule | “an Oral MEK Inhibitor” NCT00948467 ↗ |
| Route | Oral | “TAK-733 will be administered orally” NCT00948467 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL1615025 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL1615025 ↗ |